Abstract:Paddy McCrossan, 1 Michael D Shields, 2 James C McElnay 3 1 Paediatric Respiratory Medicine, Royal Belfast Hospital for Sick Children, Belfast, Northern Ireland; 2 Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland; 3 School of Pharmacy, Queen's University Belfast, Belfast, Northern Ireland Correspondence: James C McElnay, Email Asthma is the most common chronic disease in childhood. If untreated, asthma can lead to debilitating daily symptoms which affect quality of life, but more importantly can lead to fatal asthma attacks which unfortunately still occur globally. The most effective treatment strategy for controlling asthma is for the patient to follow a personalised asthma action plan (PAAP) which will invariably include regular use of an inhaled corticosteroid. To examine medication adherence in children with asthma, we collated recent evidence from systematic reviews in this area to address the following 5 key questions; What is adherence? Is there evidence that children are not adhering to preventer medication? Why is adherence poor and what are the barriers to adherence? Does good adherence improve outcomes in asthma? And lastly, how can treatment adherence be improved? Keywords: asthma, adherence, inhaler, inhaled corticosteroid, children Asthma remains the most common chronic disease in childhood. 1 Most clinical guidelines refer to children with asthma in the following age categories; 2–5 years (pre-school), 5–12 years, 12–18 (adolescents; usually regarded as adults for management). The pathophysiology of asthma involves chronic inflammation of the small and medium-sized airways (bronchi). The symptoms of asthma; wheeze, dry cough and shortness of breath, are the result of bronchoconstriction of airway smooth muscle, airway wall inflammation and mucus plugging in the bronchi which leads to airflow obstruction. The hallmark clinical feature of small/medium airway obstruction is expiratory wheeze due to turbulent flow passing through a narrowed airway. The objective marker of this is only available for children who can perform forced spirometry (typically not until at least 5 years old). For those old enough and able to perform spirometry, one important aspect of the diagnosis of asthma is the presence of bronchial lability, represented by bronchodilator reversibility. That is, the obstructive pattern seen when performing forced spirometry is reversed following the administration of a bronchodilating agent (usually a short acting beta agonist such as salbutamol). Measuring fractional exhaled nitric oxide (FeNO) can support an asthma diagnosis as an elevated FeNO (>20-25 ppb) is associated with increased airways eosinophilic inflammation. 2 Other tests which can indicate asthma as the cause of recurrent wheezing and coughing are an elevated blood eosinophilia, elevated levels of Immunoglobulin E (IgE) or positive skin prick tests to aeroallergens, all of which indicate an allergy driven response likely underpinning airway inflammation. 3 In pre-school children who cannot perform the above lung function tests, the diagnosis is confirmed after a positive trial of treatment with inhaled corticosteroids. For a trial of treatment to be effective as a diagnostic test it is important that the inhaled corticosteroid has been taken and correctly delivered to the child's airways. A clear cut response is required which may be a reduction in the day-to-day symptoms or reduction in acute wheezing episodes. If untreated, asthma can lead to debilitating daily symptoms which affect quality of life in terms of exercise tolerance and breathing difficulty, but more importantly can lead to fatal asthma attacks which unfortunately still occur globally. 4 The aim for the treatment of asthma is to: a] reduce daily interval symptoms and b] reduce the risk of future asthma attacks. Modern asthma guidelines recommend that all patients have a personalised asthma action plan (PAAP). 5,6 Adherence to the PAAP is an essential component of asthma self-management. Patients (and in younger children, their care provider) must fully understand each aspect of the plan and be capable of implementing the treatment prescribed when the patient is well (maintenance therapy) and when the patient needs to escalate their treatment (reliever therapy). Reliever therapies (short acting beta agonists [SABAs] such as salbutamol) can easily become relied upon to relieve symptoms. Overuse of reliever therapy indicates poor asthma control and is often due to poor adherence to the patient's PAAP i.e not taking their anti-inflammatory preventer. The most effective maintenance therapies reduce the inflammation in the airways by using inhaled (topical) corticosteroids. These wor -Abstract Truncated-

Severe asthma in children—a review of definitions, epidemiology, and treatment options in 2019

Evaluation and Treatment of Critical Asthma Syndrome in Children

International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

Developments in the Management of Severe Asthma in Children and Adolescents: Focus on Dupilumab and Tezepelumab

New Drugs for Pediatric Asthma

Characteristics, phenotypes, mechanisms and management of severe asthma

Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline

Options of immunotherapeutic treatments for children with asthma

Best step-up treatments for children with uncontrolled asthma: a systematic review and network meta-analysis of individual participant data

Drug therapies in severe asthma - the era of stratified medicine.

The new biologic drugs: Which children with asthma should get what?

Effectiveness of long term therapy of inhaled Steroids in Childhood Asthma: A Systemic Review

Epidemiology of severe asthma in children: a systematic review and meta-analysis

Medication Adherence in Children with Asthma

Approach to difficult-to-treat asthma in childhood: a narrative review

Severe and Difficult Asthma: Diagnosis and Management-Challenges for a Low-Resource Environment

New perspectives of childhood asthma treatment with biologics

Optimizing care for children with difficult-to-treat and severe asthma through specialist paediatric asthma centres: expert practical experience and advice

Progress in diagnosis and treatment of difficult-to-treat asthma in children

Biologics in severe asthma: A pragmatic approach for choosing the right treatment for the right patient

How I do it. Choosing the right biologic for the right patient with severe asthma